JPMorgan Chase & Co. Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $209.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $200.00 to $209.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 45.88% from the company’s previous close.

Several other brokerages have also recently weighed in on JAZZ. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $143.27 on Wednesday. The stock’s 50-day moving average is $125.87 and its two-hundred day moving average is $118.62. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market cap of $8.66 billion, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $148.06.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently bought and sold shares of the business. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $25,000. Quadrant Capital Group LLC grew its holdings in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares during the last quarter. Elequin Capital LP increased its position in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Allianz SE acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.